Andreas Plückthun

Andreas Plückthun (born May 7, 1956) is a German–Swiss biochemist and protein engineer, known for foundational contributions to antibody engineering, directed evolution technologies, and the development of alternative binding proteins. He has been a full professor of biochemistry at the University of Zurich since 1993 and is widely recognized for pioneering work that has influenced both academic research and the biotechnology industry.

His research has played a central role in establishing modern protein engineering as a discipline, particularly through the development of synthetic antibody libraries, ribosome display, and Designed Ankyrin Repeat Proteins (DARPins), which have been translated into clinical and industrial applications.

Early life and education Plückthun studied chemistry at Heidelberg University before pursuing graduate studies at the University of California, San Diego, where he obtained a Ph.D. in 1982 under Edward Dennis. His doctoral work focused on enzymatic catalysis at interfaces.

Research Antibody engineering and synthetic libraries Plückthun's early work demonstrated the expression of functional antibody fragments in Escherichia coli, thereby overcoming a major technical barrier in recombinant antibody production. This work enabled the development of modern antibody engineering techniques and laid the groundwork for the first fully synthetic antibody libraries.

These libraries, including modular combinatorial systems, allowed rapid generation of antibodies without immunization and have since become widely used in both research and therapeutic development. Several antibodies derived from such technologies have been translated into clinical applications.

Designed Ankyrin Repeat Proteins (DARPins)

Building on insights from antibody stability and folding, Plückthun developed Designed Ankyrin Repeat Proteins (DARPins), a class of engineered binding proteins designed to overcome limitations of conventional antibodies.

DARPins exhibit high stability, strong binding affinity, and efficient expression across multiple systems. They have been developed into therapeutic candidates and research tools, including applications targeting intracellular proteins and complex biological pathways.

Using ribosome display, proteins have been evolved to achieve very high binding affinities, and specialized variants of the method have been developed to improve protein stability and folding efficiency. These technologies have become widely adopted tools in protein engineering and biotechnology.

By combining directed evolution with high-throughput selection techniques, these methods enabled improved expression, stability, and structural analysis of GPCRs using crystallography, cryo-electron microscopy, and other approaches, as well as enabling the direct high-throughput screening for binding of ligands.

Applications demonstrated in preclinical models include targeted delivery to tumor cells and immune cells, enabling localized therapeutic expression of antibodies and cytokines. Co-founder of Molecular Partners AG (2004), developing DARPin-based therapeutics

Awards and honors Christian B. Anfinsen Award of the Protein Society (2016) European Research Council (ERC) Senior Investigator Grant (2011) ERC Synergy Grant (2018) Wilhelm-Exner Medal (2002) Grand Prix Européen d'Innovation (2002) J.P. Morgan Chase Health Award (2002) Young Investigator Award of the German Chemical Industry (1990)

Member of European Molecular Biology Organization (EMBO) Member of German Academy of Sciences (Leopoldina)

Scientific impact

Plückthun has authored more than 550 scientific publications, with over 60,000 citations and an h-index exceeding 130, reflecting sustained influence across multiple areas of protein science.

His work continues to influence fields including antibody therapeutics, structural biology, and synthetic biology, with ongoing research expanding into targeted gene delivery and precision medicine approaches as well as new approaches to design binding molecules.